Revive Therapeutics Ltd - RVVTF STOCK NEWS

Welcome to our dedicated news page for Revive Therapeutics (Ticker: RVVTF), a resource for investors and traders seeking the latest updates and insights on Revive Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revive Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revive Therapeutics's position in the market.

04/23/2024 07:00 AM

News

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

Rhea-AI Summary

Revive Therapeutics announces FDA granting Type C meeting request for clinical study of Bucillamine to treat Long COVID. The meeting is scheduled for June 9, 2024. Bucillamine has shown potential in treating long COVID and has anti-inflammatory and antiviral properties. The Company aims to leverage previous research to advance clinical development.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.76%

Tags

04/18/2024 07:00 AM

News

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Rhea-AI Summary

Revive Therapeutics announced that the FDA has accepted the meeting request for their Revive LC POC Lateral Flow Test Kit, a potential blood biomarker diagnostic for long COVID. The meeting date is set for June 7, 2024. The Company aims to develop an in vitro diagnostic device to aid in the detection of post COVID-19 conditions, addressing the lack of an FDA-approved clinical diagnosis for long COVID, which affects at least 10% of SARS-CoV-2 infections. Revive has entered into a license agreement for the intellectual property of novel blood biomarkers that characterize long COVID.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.76%

Tags

04/02/2024 07:30 AM

News

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Rhea-AI Summary

Revive Therapeutics provides an update on a clinical study evaluating oral psilocybin for methamphetamine use disorder. The study shows promising initial efficacy, with potential for future commercial initiatives and exclusive access to valuable intellectual property.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.55%

Tags

03/27/2024 09:08 AM

News

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

Rhea-AI Summary

Revive Therapeutics submits Type C meeting request package to FDA for evaluation of Bucillamine as a potential treatment for long-term COVID. The Company aims to address long COVID symptoms and potential economic costs through leveraging previous clinical trial data.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.64%

Tags

03/19/2024 07:00 AM

News

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

Rhea-AI Summary

Revive Therapeutics announced that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine as a potential treatment for long COVID. The Company expects to submit the request soon. Bucillamine has shown promise in previous studies for COVID-19 treatment, and research suggests its potential for long COVID. These developments could have significant implications for medical treatment and the economic impact of long COVID.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-12.16%

Tags

03/12/2024 07:00 AM

News

Revive Therapeutics Provides Corporate Update

Rhea-AI Summary

Revive Therapeutics Ltd. provides a corporate update on research initiatives with Bucillamine for long COVID and nerve agent exposure. The company aims to develop Bucillamine as a treatment for nerve agent exposure and explore its potential for long COVID. Additionally, Revive is advancing the development of a blood biomarker diagnostic for long COVID.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

16.52%

Tags

02/01/2024 07:30 AM

News

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

Rhea-AI Summary

Revive Therapeutics Ltd. announced its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The company aims to advance the clinical development of Bucillamine by leveraging existing data from its previous Phase 3 clinical trial and is preparing a clinical package for presentation to the FDA and international health regulatory bodies. The CDC estimates that 7.5 percent of U.S. adults have long COVID symptoms, and the economic cost could be as much as $3.7 trillion. The results of the Study evaluating the safety and efficacy of oral Bucillamine in patients with mild to moderate COVID-19 showed promising outcomes, with no deaths and a low hospitalization rate. Thiol-based drugs like Bucillamine have shown potential in inhibiting SARS-CoV-2 cell entry and live virus infection, providing a rationale for testing them as a novel treatment for COVID-19.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.55%

Tags

01/16/2024 07:00 AM

News

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

Rhea-AI Summary

Revive Therapeutics Ltd. announced an update on the project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada. The research protocol has been finalized, and the project is expected to be completed by the end of Q2-2024. Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors. The results from this research, if promising, will determine further studies to facilitate Health Canada approval for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and potentially begin initial studies for efficacy against mild traumatic brain injury caused by concussive or explosive forces.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

01/10/2024 07:00 AM

News

Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

Rhea-AI Summary

Revive Therapeutics Ltd. (RVVTF) completes the formulation development work of its next-generation lyophilized formulation of Bucillamine, with potential applications in treating public health medical emergencies. The new formulation has the potential to increase Bucillamine delivery per dosing unit and create a parenteral injection product with minimal formulation additives. Revive plans to evaluate the new formulation in a clinical study this year and expects to have it ready for clinical evaluation in 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.4%

Tags

12/20/2023 12:54 PM

News

Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders

Rhea-AI Summary

Revive Therapeutics Ltd. (RVVTF) announces successful annual general and special meeting of shareholders, re-elects Board of Directors, and approves 10% rolling stock option plan.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.7%

Tags